In 2025, an estimated 226,000+ people will be diagnosed with lung or bronchus cancer, with nearly 124,000 lives lost. One of the most effective ways to catch it early? Screening.

Students and educators from around the globe had a behind-the-scenes look at AtriCure's headquarters in Mason, OH to learn how to design, test, and assemble devices and technologies for the treatment of Afib and reducing post-operative pain.

In partnership with Ohio Life Sciences Association, the BioPathways Virtual Field Trip brought STEM education, career exploration and world-class innovation directly to classrooms everywhere to discover the essential skills that fuel medical treatment breakthroughs for improving patient outcomes.

Lung cancer will impact more than 226,000 people in the U.S. this year—and claim over 124,000 lives.​

It’s the leading cause of cancer death, but it doesn’t have to be. Screening saves lives.​

Talk to your healthcare provider about a lung cancer screening today. ​

Resources: <a href="https://okt.to/nEgd5P&quot; target="_blank">https://okt.to/nEgd5P</a&gt; <a href="https://www.facebook.com/hashtag/​

LungCancerAwareness" target="_blank">​

#LungCancerAwareness</a>

In a more difficult-to-treat population of patients, those with long-standing persistent AF, freedom from atrial arrhythmias (AA)* after hybrid ablation was comparable between the real-world TRAC-AF Registry and hybrid ablation arm of the CONVERGE Trial Data. ​

<a href='https://www.linkedin.com/feed/hashtag/?keywords=HybridAFTherapy&highlig…; target='_blank'>#HybridAFTherapy</a>  <a href='https://www.linkedin.com/feed/hashtag/?keywords=CardiacSurgery&highligh…; target='_blank'>#CardiacSurgery</a> ​
 ​
*Defined as AF, atrial flutter or atrial tachyarrhythmias

The DEEP Trial results demonstrate improved quality of life in patients with persistent and long-standing persistent Afib who underwent hybrid ablation and LAA exclusion with an AtriClip®​ device.​

Read the data here: <a href="https://t.co/FkHUl2h6SV&quot; target="_blank">https://t.co/FkHUl2h6SV</a&gt; ​

<a href="https://twitter.com/hashtag/Epeeps?src=hashtag_click&quot; target="_blank">#Epeeps</a> <a href="https://twitter.com/hashtag/HybridAFTherapy?src=hashtag_click&quot; target="_blank">#HybridAFTherapy</a>

Amputation procedures often come with significant post-surgical and chronic pain.​

Unlike alternative treatments for pain management, Cryo Nerve Block is an innovative, non-opioid therapy that manages symptoms at the time of the procedure.​

Discover how: <a href="https://t.co/1Et5i3rTYb&quot; target="_blank">https://t.co/1Et5i3rTYb</a&gt;

The AtriClip PRO-Mini® device delivers omni-directional movement for consistent up-and-down and side-to-side range of motion—designed to navigate anatomical variability with increased visualization and a lower profile.​​

Learn more: <a href="https://t.co/c8T1q0pwxy&quot; target="_blank">https://t.co/c8T1q0pwxy</a&gt; ​

<a href="https://twitter.com/hashtag/AtriClip?src=hashtag_click&quot; target="_blank">#AtriClip</a> <a href="https://twitter.com/hashtag/LAAE?src=hashtag_click&quot; target="_blank">#LAAE</a>

Afib carries a worse survival rate than many cancers. Yet we don’t treat it with the same urgency.  
​
Every patient with Afib deserves rhythm restoration, not a wait-and-see approach. ​

If it were cancer, we wouldn’t delay treatment. Why delay Afib care?​

Learn more:

Temporarily blocking peripheral nerve pain signals, the cryoXT™ probe plays a key role in the multimodal pain management plan. ​

The effect can last for several months and may aid in the prevention of residual limb pain and phantom limb pain.​

Discover how:

Surgical resection for lung cancer can be challenging—not just for the patient, but for their recovery.​

Cryo Nerve Block offers a way to minimize post-op pain, replacing prolonged discomfort with temporary numbness that fades over time.​

Learn more: <a href="https://t.co/k3Rgq2witN&quot; target="_blank">https://t.co/k3Rgq2witN</a&gt;